Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Melanoma 5Brain Neoplasms 5Neuroblastoma 3Seminoma 2Meningioma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Glioblastoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Somatostatinoma 1Rhabdomyosarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Paraganglioma 1Paget Disease, Extramammary 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

pembrolizumab 2Specimen Handling 2Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Diffusion Tensor Imaging 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × CTLA-4 Antigen × CNS × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡